Dr. Wong is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Roswell Park Cancer
Elm and Carlton Street
Buffalo, NY 14263Fax+1 855-655-9664
Education & Training
- University of Toronto Faculty of MedicineClass of 1989
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2016 - 2026
- NY State Medical License 2003 - 2025
- CA State Medical License 2010 - 2024
- OK State Medical License 2020 - 2021
- PA State Medical License 1998 - 2004
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2006 Nov 01
- Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
Publications & Presentations
PubMed
- Immune Checkpoint Inhibitor Therapy for Periocular Merkel Cell Carcinoma.Joshua Hohlbein, Janet Fan, Hila Goldberg, Tracy Lu, Anastasios Maniakas
Ophthalmology. 2024-08-08 - Survival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma.Chantal Saberian, Denái R Milton, Julie Simon, Rodabe N Amaria, Adi Diab
Neuro-Oncology Practice. 2024-08-01 - Author Correction: Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.Isabella C Glitza Oliva, Sherise D Ferguson, Roland Bassett Jr, Alexandra P Foster, Ida John
Nature Medicine. 2024-06-01
Press Mentions
- "Taking the Journey - Ella's Story" - A UC Davis Health Patient TestimonialOctober 17th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: